The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)
 
Kenji Tamura
No Relationships to Disclose
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Sumitomo Dainippon; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Junji Tsurutani
Honoraria - AstraZeneca; Eisai; Kyowa Hakko Kirin; Novartis; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Asahi Kasei; Eisai
Research Funding - Daiichi Sankyo; Eisai; Roche
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Shanu Modi
Speakers' Bureau - Genentech
Research Funding - Daiichi Sankyo; Novartis; Roche/Genentech; Seagen; Synta
 
Haeseong Park
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst); Vertex (Inst)
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - Genentech/Roche
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Seagen
Research Funding - Genentech
 
Yasuaki Sagara
No Relationships to Disclose
 
Charles H. Redfern
No Relationships to Disclose
 
Rashmi Krishna Murthy
Consulting or Advisory Role - Daiichi Sankyo; Genentech
Research Funding - Daiichi Sankyo; Genentech/Roche; Merrimack (Inst); Oncothyreon (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Oncothyreon
 
Rebecca A. Redman
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yoshihiko Fujisaki
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Masahiro Sugihara
Employment - Daiichi Sankyo
 
Lin Zhang
Employment - Daiichi Sankyo; EMD Serono
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo; EMD Serono
 
Javad Shahidi
Employment - Daiichi Sankyo; Lilly
 
Antoine Yver
Employment - AstraZeneca; Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Shunji Takahashi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Novartis; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis